Challenges, considerations, and approaches for developing a cost-effectiveness model for the adjuvant treatment of muscle-invasive urothelial carcinoma: with a spotlight on nivolumab versus placebo-Reference-Cited by-同舟云学术

Challenges, considerations, and approaches for developing a cost-effectiveness model for the adjuvant treatment of muscle-invasive urothelial carcinoma: with a spotlight on nivolumab versus placebo

Published:2024-03-25 Issue:1 Volume:27 Page:473-481
ISSN:1369-6998
Container-title:Journal of Medical Economics
language:en
Short-container-title:Journal of Medical Economics

Author:

Teitsson Siguroli¹^ORCID,Brodtkorb Thor-Henrik²^ORCID,Kurt Murat³,Patel Miraj Y.³^ORCID,Poretta Tayla³,Knight Christopher⁴,Kamgar Farzam²,Palmer Stephen⁵^ORCID

Affiliation:

1. Bristol Myers Squibb, Uxbridge, UK

2. RTI Health Solutions, Ljungskile, Sweden

3. Bristol Myers Squibb, Princeton, NJ, USA

4. RTI Health Solutions, Manchester, UK

5. Centre for Health Economics, University of York, York, UK

Publisher

Informa UK Limited

Link

https://www.tandfonline.com/doi/pdf/10.1080/13696998.2024.2322394

Reference37 articles.

1. American Cancer Society. What is bladder cancer? 2022. https://www.cancer.org/cancer/types/bladder-cancer/about/what-is-bladder-cancer.html.

2. European Association of Urology Guidelines on Upper Urinary Tract Urothelial Carcinoma: 2020 Update

3. Johns Hopkins Greenberg Bladder Cancer Institute. Upper tract urothelial cancer. 2017. https://www.hopkinsmedicine.org/greenberg-bladder-cancer-institute/utuc/.

4. Epidemiology, aetiology and screening of bladder cancer

5. American Joint Committee on Cancer. Cancer staging form supplement. 8th ed. New York: Springer; 2018.

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Cost-effectiveness of nivolumab versus surveillance for the adjuvant treatment of patients with urothelial carcinoma who are at high risk of recurrence: a US payer perspective;Journal of Medical Economics;2024-04-04